Compare Hilton Hotels Corporation Common Stock (HLT) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hilton Hotels Corporation Common Stock vs Merck & Co., Inc. — how do they compare? Hilton Hotels Corporation Common Stock trades at $325.85 (market cap $72.76B), while Merck & Co., Inc. trades at $144.83 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 4.8× Hilton Hotels Corporation Common Stock's market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Hilton Hotels Corporation Common Stock for 138 Days and Merck & Co., Inc. for 98 Days on average.
| HLT | MRK | |
|---|---|---|
Market Cap | $72.76B | $351.28B |
Volume | 1,148,634 | 7,969,665 |
Sector | Consumer Cyclical | Health |
52-Week High | $350.22 | $156.43 |
52-Week Low | $256.96 | $82.49 |
Typical Hold Time | 138 Days | 98 Days |
Enterprise Value | $85.78B | $398.04B |
Dividend Yield | 0.19% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hilton Worldwide (HLT) trades at $320.5, down 0.65% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $348.11. The company has consistently beaten earnings expectations in recent quarters, with Q3 2026 results expected soon. Revenue has grown steadily from $8.8B in 2022 to $12.04B in 2025, though net income margins have fluctuated. Recent news highlights institutional buying and positive travel trends for 2027.
The outlook for HLT is positive, supported by strong earnings performance, analyst optimism, and growth in travel demand. Key risks include high debt levels, with debt-to-asset ratio rising to 73.88% in 2025, and sensitivity to economic cycles affecting travel spending. The stock offers potential upside to the consensus target, but investors should monitor debt management and macroeconomic conditions.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
